Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: Results from the phase II BEVACOLOR study

Clinical Colorectal Cancer

Volumn 11, Issue 1, 2012, Pages 38-44

  Bennouna, Jaafar ^a   Borg, Christophe ^b   Delord, Jean Pierre ^c   Husseini, Faress ^d   Trillet Lenoir, Véronique ^e   Faroux, Roger ^f   François, Eric ^g   Ychou, Marc ^h   Goldwasser, François ⁱ   Bouché, Olivier ^j   Senellart, Helene ^a   Kraemer, Sandrine ^k   Douillard, Jean Yves ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d Pasteur Hospital   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f Centre Hospitalier Departemental   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ Centre Hospitalier Universitaire Cochin ^*  (France)

^j SERVICE DE DERMATOLOGIE   (France)

^k Roche France   (France)

more..

Author keywords

Anti angiogenic therapy; Chemotherapy; Metastatic colorectal cancer; Phase II

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RELAPSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 84861569539     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.05.002     Document Type: Article

References (28)

1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology v3 2010. Available at http://www.nccn.org/professionals/physician-gls/ PDF/colon.pdf. Accessed July 14 2010.
2. Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer:ESMO clinical practice guidelines for treatment. Ann Oncol 2010; 21 Suppl 5:v93-7.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502-8.
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
6. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706-12.
7. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-9.
8. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
9. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19:1720-6.
10. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008; 26:4544-50.
11. Hebbar M, Tournigand C, Lledo G, et al. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest 2006; 24:154-9.
12. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706-13.
13. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23: 9441-2.
14. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44.
15. Vincenzi B, Santini D, Russo A, et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximabrefractory colorectal cancer: a single-center phase 2 trial. Cancer 2009; 115:4849-56.
16. Timotheadou E, Papakostas P, Tsavdaridis D, et al. Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine- pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG). Tumori 2005; 91:309-13.
17. Tsutsumi S, Yamaguchi S, Ide M, et al. Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU. Hepatogastroenterology 2006; 53:196-200.
18. Ziras N, Potamianou A, Varthalitis I, et al. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology 2006; 70:106-14.
19. Chang AY, Lopes G, Hsin KW, et al. Phase II trial of 5-fluorouracil/ leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. Clin Colorectal Cancer 2007; 6:646-51.
20. Maindrault-Goebel F, de Gramont A, Louvet C, et al. For the Oncology Multidisciplinary Research Group (GERCOR). High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 2001; 37:1000-5.
21. Shin SJ, Ahn JB, Choi HJ, et al. The combination of capecitabine and irinotecan in treating 5-fluorouracil- and oxaliplatin-pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol 2008; 61:75-81.
22. Stathopoulos GP, Rigatos SK, Stathopoulos JG, et al. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am J Clin Oncol 2005; 28:565-9.
23. Liévre A, Samalin E, Mitry E, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009; 9:347.
24. Yildiz R, Buyukberber S, Uner A, et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest 2010; 28:33-7.
25. SaifMW,Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006; 5:553-66.
26. McKibbin T, Frei CR, Greene RE, et al. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008; 13:876-85.
27. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26:5326-34.
28. Bekaii-Saab TS, Bendell JC, Cohn AL, et al. Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): initial results from ARIES, a second BV observational cohort study (OCS). J Clin Oncol 2010; 28:15s(suppl):abstract 3595.